Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg

Aim. Estimation of the liver steatosis and fibrosis incidence with transient elastography and the controlled attenuation parameter in residents of St. Petersburg.

Materials and methods. A prospective open single-centre population study included history, anthropometric and laboratory data on 318 outpatients aged 24—89 years (mean age 52.6 ± 14.6 years). The degrees of steatosis (assessed with the controlled attenuation parameter as ultrasound amplitude dropdown quantification in liver) and fibrosis were determined with a Fibroscan 502 Touch unit (Echosens, France).

Results. Hepatic steatosis of predominantly high degree was revealed in 44.7%, combined fibrosis and steatosis — in 28%; isolated fibrosis of various stage — in 2.5%, no structural changes — in 24.8% individuals. The growth of body mass index and waist circumference significantly correlated in women with pronounced liver changes. Serum transaminase activity increased with more severe liver changes, being statistically significant for aspartic transaminase only.

Conclusion. A high incidence of primary liver steatosis and fibrosis in residents of St. Petersburg warrants improved diagnostic algorithms and routine preventive measures. Transient elastography with the controlled attenuation parameter estimation provides a convenient non-invasive screening for hepatic fibrosis and steatosis.

1. Vyalov S.S. Screening methods for existing liver fibrosis. Rus Arch Intern Med. 2013;3(5):48-57 (In Russ.). DOI: 10.20514/2226-6704-2012-0-3-48-57

2. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatol. 2005;42:44-52. DOI: 10.1002/hep.20734

3. Ivashkin V.T., Drapkina O.M., Mayev I.V., Trukhmanov A.S., Blinov D.V., Palgova L.K., et al. Prevalence of non-alcoholic fatty liver disease in outpatients in the Russian Federation: results of the DIREG 2 study. Rus J Gastroenterol Hepatol Coloproctol. 2015;6:31-41 (In Russ.).

4. Parolaa M., Pinzanib M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65(2):37-55. DOI: 10.1016/j.mam.2018.09.002

5. Didenko V.I. Modern advances in the assessment of liver steatosis. Gastroenterol. 2015;3(57):94-9 (In Russ.).

6. Klyaritskaya I.L., Shelikhova E.O., Moshko Yu.A., Semenikhina E.V., Krivoy V.V., Tsapyak T.A. Elastometry in the diagnosis of liver diseases. Crim Ther J. 2017;2(33):28-35 (In Russ.).

7. Boursier J., Vergniol J., Guillet A., Hiriart J.B., Lannes A. Diagnostic accuracy and predictive value of elastometry with Fibroscan and blood tests to detect fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2016;65: 570-8 (In Russ.).

8. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004

9. Dietrich C.F., Bamber J., Berzigotti A., Bota S., Cantisani V., Castera L., et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med. 2017;38(4):16-47. DOI: 10.1055/s-0043-103952

10. Zhang X., Wong G.L.H., Wong V.W.S. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26(2):128-41. DOI: 10.3350/cmh.2019.0001n

11. Komova A.G., Mayevskaya M.V., Ivashkin V.T. Principles of effective diagnosis of diffuse liver diseases at the outpatient stage. Rus J Gastroenterol Hepatol Coloproctol. 2014;6:36-41 (In Russ.).

12. Karlas T., Petroff D., Sasso M., Fan J.G., Mi Y.Q. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. Hepatol. 2017;66(5):1022-30. DOI: 10.1016/j.jhep.2016.12.022

13. Pandyarajan V., Gish R.G., Alkhouri N., Noureddin M. Screening for Nonalcoholic Fatty Liver Disease in the Primary Care. Clinic Gastroenterol Hepatol. 2019;15(7):357-65.

14. Wong V., Vergniol J., Wong G. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatol. 2010;51(2):454-62. DOI: 10.1002/hep.23312

15. Karlas T., Petroff D., Garnov N. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS ONE. 2014;9(3):e91987. DOI: 10.1371/journal.pone.0091987

16. Paik J., Golabi P., Younossi Y., Mishra A., Younossi Z. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease. Hepatol. 2020; 72(5):1605-16. DOI: 10.1002/hep.31173

17. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol. 2016;64(1):73-84. DOI: 10.1002/hep.28431

18. Palgova L.K., Baranovsky A.Yu., Ushakova T.I., Yurkina A.S., Blinov D.V. Epidemiological features of non-alcoholic fatty liver disease in the northwestern region of Russia (results of an open multicenter prospective study DIREG 2). Bulletin of St. Petersburg University. Med. 2017; 12(2):118-35 (In Russ.). DOI: 10.21638/11701/spbu11.2017.201

19. Komova A.G., Mayevskaya M.V., Ivashkin V.T. Principles of effective diagnosis of diffuse liver diseases at the outpatient stage. Rus J Gastroenterol Hepatol Coloproctol. 2014;6:36-41 (In Russ.).

20. Li L., Liu D.-W., Yan H.-Y., Wang Z.-Y., Zhao S.-H. Obesity is an independent risk factor for non alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obesity reviews. 2016;17(6):510-9. DOI: 10.1111/obr.12407

21. Popova I.R. Prevalence of diseases of the digestive system in patients with overweight and obesity. Rus J Gastroenterol Hepatol Coloproctol. 2012;22(5):24-30 (In Russ.).

22. Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating non-alcoholic steatohepatitis from alcoholic liver disease. American J of Gastroenter-ol.1999;94:1018. DOI: 10.1111/j.1572-0241.1999.01006

23. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Tikhonov I.N., Shirokova Ye.N., Buyeverov A.O., et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctol. 2016;2:24-42 (In Russ.). DOI: 10.22416/1382-4376-2016-26-2-24-42